Wells Fargo & Company Has Lowered Expectations for Tandem Diabetes Care (NASDAQ:TNDM) Stock Price

Tandem Diabetes Care (NASDAQ:TNDM) had its target price decreased by stock analysts at Wells Fargo & Company from $27.00 to $25.00 in a report issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the medical device company’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 56.13% from the stock’s previous close.

A number of other equities analysts also recently commented on TNDM. William Blair started coverage on shares of Tandem Diabetes Care in a report on Friday, August 21st. They set an “outperform” rating for the company. Citigroup dropped their price target on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, September 30th. Canaccord Genuity Group set a $40.00 price target on shares of Tandem Diabetes Care in a research report on Friday, August 7th. UBS Group assumed coverage on shares of Tandem Diabetes Care in a research note on Tuesday, July 28th. They set a “neutral” rating and a $18.00 price target for the company. Finally, Truist Financial decreased their price objective on Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $27.08.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ TNDM opened at $16.01 on Friday. The company has a quick ratio of 2.65, a current ratio of 3.18 and a debt-to-equity ratio of 4.62. The business’s 50 day moving average is $17.74 and its two-hundred day moving average is $18.90. The company has a market cap of $1.11 billion, a P/E ratio of -17.55 and a beta of 1.59. Tandem Diabetes Care has a 12 month low of $12.26 and a 12 month high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, November 5th. The medical device company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.15. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The business had revenue of $283.69 million during the quarter, compared to analysts’ expectations of $265.85 million. During the same quarter last year, the company earned ($0.31) earnings per share. The firm’s revenue was up 13.8% on a year-over-year basis. On average, equities analysts expect that Tandem Diabetes Care will post -0.66 EPS for the current year.

Insider Transactions at Tandem Diabetes Care

In related news, Director Christopher J. Twomey sold 1,700 shares of Tandem Diabetes Care stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total transaction of $32,555.00. Following the completion of the transaction, the director directly owned 24,434 shares of the company’s stock, valued at $467,911.10. This trade represents a 6.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is owned by corporate insiders.

Institutional Trading of Tandem Diabetes Care

Several hedge funds have recently modified their holdings of TNDM. Maryland State Retirement & Pension System bought a new position in shares of Tandem Diabetes Care in the third quarter valued at approximately $249,000. Fulcrum Asset Management LLP boosted its holdings in shares of Tandem Diabetes Care by 1,463.6% in the 3rd quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company’s stock worth $73,000 after acquiring an additional 4,098 shares in the last quarter. Provenance Wealth Advisors LLC bought a new stake in Tandem Diabetes Care during the 3rd quarter worth approximately $158,000. Summit Global Investments grew its position in Tandem Diabetes Care by 13.9% during the 3rd quarter. Summit Global Investments now owns 24,753 shares of the medical device company’s stock worth $404,000 after acquiring an additional 3,017 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in Tandem Diabetes Care by 31.3% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 34,400 shares of the medical device company’s stock worth $561,000 after acquiring an additional 8,200 shares during the last quarter.

More Tandem Diabetes Care News

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q3 revenue was $283.7 million, up 13.8% year over year and above analyst estimates of $265.9 million. The company’s loss of $0.10 per share was also narrower than expected. Tandem Q3 2026 financial results
• Positive Sentiment: Gross margin improved to 57%, up 2.7 percentage points from a year earlier. Tandem also reported about 33,000 pump shipments, supporting evidence of business growth. Tandem Q3 2026 financial results
• Positive Sentiment: Management forecast 2026 sales of $1.065 billion to $1.085 billion, giving investors a full-year revenue range to assess against the company’s growth trajectory. 2026 sales outlook and CEO transition
• Neutral Sentiment: Tandem named Jeannette Bankes as president and CEO as John Sheridan plans to retire at the end of 2026. Naming a successor provides advance notice, though investors may watch for details on strategic continuity during the transition. Tandem names Jeannette Bankes CEO

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.